cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.n3cr9g
title: Occurrence Download

description: A dataset listing the 349 species recorded in GBIF matching the query:
{
 "and" : [
 "DatasetKey is NIWA Invertebrate Collection",
 "Geometry POLYGON((174.57318 -36.77466,174.62909 -36.83697,174.66429 -36.91239,174.73401 -36.89363,174.71488 -36.86339,174.75901 -36.8566,174.79018 -36.87728,174.79359 -36.87655,174.83215 -36.87512,174.83739 -36.8566,174.87011 -36.85814,174.84326 -36.92912,174.84141 -36.96862,174.89942 -36.94856,174.88986 -36.90505,174.90652 -36.88869,174.93275 -36.90042,174.9309 -36.93468,174.95096 -36.92665,174.96701 -36.95288,174.98336 -36.92634,175.00095 -36.93468,175.00157 -36.89271,175.03459 -36.88653,175.04724 -36.88777,175.06422 -36.91523,175.07146 -36.92938,175.0607 -36.97,175.09838 -36.95776,175.139 -36.94895,175.15956 -36.96021,175.19039 -36.94699,175.2266 -36.96314,175.27016 -36.99398,175.30439 -37.20898,175.37157 -37.24494,175.45957 -37.23264,175.55514 -37.19006,175.55911 -37.14296,175.55041 -37.08881,175.50688 -36.95255,175.43781 -36.87212,175.4889 -36.85131,175.53831 -36.78722,175.49629 -36.71445,175.4718 -36.60295,175.45803 -36.57451,175.35053 -36.47503,175.35043 -36.47365,175.3502 -36.47286,175.3502 -36.47212,175.34779 -36.4721,175.34465 -36.46926,175.52571 -36.34555,175.45052 -36.24949,175.38712 -36.21175,175.34729 -36.22138,175.31272 -36.20655,175.11312 -36.18197,175.08277 -36.21874,175.0507 -36.21959,174.82326 -36.27731,174.80116 -36.28711,174.79687 -36.29811,174.78673 -36.2933,174.76714 -36.30334,174.67577 -36.33374,174.67075 -36.38643,174.6844 -36.40534,174.68264 -36.41362,174.66666 -36.41693,174.65446 -36.60803,174.68191 -36.60714,174.68209 -36.6135,174.65666 -36.61682,174.69046 -36.67191,174.70751 -36.68908,174.72102 -36.7342,174.69674 -36.71336,174.59895 -36.72801,174.57318 -36.77466))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Animalia"
 ]
}

 The dataset's 349 records were derived from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022565-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.68426j
title: Occurrence Download

description: A dataset containing 1431 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-74.88434 40.58207,-86.11311 31.08461,-80.72132 17.2836,-55.09795 14.85977,-56.43354 40.9778,-74.88434 40.58207))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Sargassaceae",
 "Year 1990-2025"
 ]
}

 The dataset includes 1431 records from 40 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022587-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.6st44a
title: Occurrence Download

description: A dataset containing 178 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((17.70539 -34.94026,19.96907 -34.94026,19.96907 -33.06379,17.70539 -33.06379,17.70539 -34.94026))",
 "HasGeospatialIssue is false",
 "TaxonKey is Pontederia L."
 ]
}

 The dataset includes 178 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022588-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5517/ccdc.csd.cc2621cq
title: CCDC 2027752: Experimental Crystal Structure Determination

description: Related Article: Marina V. Volostnykh, Gayane A. Kirakosyan, Anna A. Sinelshchikova, Elizaveta V. Ermakova, Yulia G. Gorbunova, Aslan Yu. Tsivadze, Sergey M. Borisov, Michel Meyer, Lhoussain Khrouz, Cyrille Monnereau, Stephane Parola, Alla Bessmertnykh-Lemeune|2025|Dalton Trans.|54|2340|doi:10.1039/D4DT03068K
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5281/zenodo.13323679
title: Sewage - deep sequencing data
DOI: 10.5281/zenodo.13323680
title: Sewage - deep sequencing data
DOI: 10.15468/dl.s23evw
title: Occurrence Download

description: A dataset containing 1413004 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Sri Lanka",
 "Year 2020-2025"
 ]
}

 The dataset includes 1413004 records from 46 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022549-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17632/rhtr5yfpcn.1
title: Circulating MAIT cells in multiple sclerosis and amyotrophic lateral sclerosis

description: Data referred to the study financed by the Ministry of Health (RF-2018-12367731) and published in the article https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1436717/full
DOI: 10.15468/dl.wgcnf5
title: Occurrence Download

description: A dataset containing 3485 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Cyperus alternifolius subsp. flabelliformis Kük., Cyperus gradatus Forssk., Cyperus alternifolius var. albovariegatus Anon., Cyperus alternifolius subsp. variegatus Hovey, Cyperus alternifolius subsp. variegatus Veitch ex J.Dix, Cyperus flagellatus Hochst., Cyperus involucratus Rottb., Cyperus alternifolius subsp. variegatus Veitch, Cyperus flabelliformis Rottb., Cyperus petersianus Boeckeler, Cyperus alternifolius subsp. albovariegatus, Cyperus proximus Steud., Cyperus alternifolius var. flabelliformis (Rottb.) M.R.Almeida, Cyperus alternifolius var. petersianus (Boeckeler) Kük., Cyperus alternifolius subsp. petersianus (Boeck.) Kük.)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2000"
 ]
}

 The dataset includes 3485 records from 146 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022591-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.gmfk8m
title: Occurrence Download

description: A dataset containing 793 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is NIWA Invertebrate Collection",
 "Geometry POLYGON((174.57318 -36.77466,174.62909 -36.83697,174.66429 -36.91239,174.73401 -36.89363,174.71488 -36.86339,174.75901 -36.8566,174.79018 -36.87728,174.79359 -36.87655,174.83215 -36.87512,174.83739 -36.8566,174.87011 -36.85814,174.84326 -36.92912,174.84141 -36.96862,174.89942 -36.94856,174.88986 -36.90505,174.90652 -36.88869,174.93275 -36.90042,174.9309 -36.93468,174.95096 -36.92665,174.96701 -36.95288,174.98336 -36.92634,175.00095 -36.93468,175.00157 -36.89271,175.03459 -36.88653,175.04724 -36.88777,175.06422 -36.91523,175.07146 -36.92938,175.0607 -36.97,175.09838 -36.95776,175.139 -36.94895,175.15956 -36.96021,175.19039 -36.94699,175.2266 -36.96314,175.27016 -36.99398,175.30439 -37.20898,175.37157 -37.24494,175.45957 -37.23264,175.55514 -37.19006,175.55911 -37.14296,175.55041 -37.08881,175.50688 -36.95255,175.43781 -36.87212,175.4889 -36.85131,175.53831 -36.78722,175.49629 -36.71445,175.4718 -36.60295,175.45803 -36.57451,175.35053 -36.47503,175.35043 -36.47365,175.3502 -36.47286,175.3502 -36.47212,175.34779 -36.4721,175.34465 -36.46926,175.52571 -36.34555,175.45052 -36.24949,175.38712 -36.21175,175.34729 -36.22138,175.31272 -36.20655,175.11312 -36.18197,175.08277 -36.21874,175.0507 -36.21959,174.82326 -36.27731,174.80116 -36.28711,174.79687 -36.29811,174.78673 -36.2933,174.76714 -36.30334,174.67577 -36.33374,174.67075 -36.38643,174.6844 -36.40534,174.68264 -36.41362,174.66666 -36.41693,174.65446 -36.60803,174.68191 -36.60714,174.68209 -36.6135,174.65666 -36.61682,174.69046 -36.67191,174.70751 -36.68908,174.72102 -36.7342,174.69674 -36.71336,174.59895 -36.72801,174.57318 -36.77466))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Animalia"
 ]
}

 The dataset includes 793 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022592-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.58032/agh/vfcsul
title: Predicting sensitivity to glucose in metal sulfides: A structural and surface characterization study - research data

description: The aim of this dataset is to compile and share the experimental data collected for the article titled "Predicting sensitivity to glucose in metal sulfides: A structural and surface characterization study". The research focused on understanding the structural, morphological, and surface properties of metal sulfides and their implications for sensor development. The dataset includes results from: X-ray Diffraction (XRD), Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), Raman Spectroscopy, X-ray Photoelectron Spectroscopy (XPS), and electrochemical measurements. This comprehensive dataset supports further exploration into the electrochemical behavior of metal sulfides and their potential applications in glucose sensing technologies.
DOI: 10.48597/upf6-p65q
title: Measurement of Heavy metals at Lahemaa

description: Measurement of Heavy metals at Lahemaa
DOI: 10.48597/w4ru-ftjg
title: Measurement of Heavy metals at Lahemaa

description: Measurement of Heavy metals at Lahemaa
DOI: 10.48597/wub5-k822
title: Measurement of Heavy metals at Lahemaa

description: Measurement of Heavy metals at Lahemaa
DOI: 10.48597/2zpz-qnrq
title: Measurement of Heavy metals at Lahemaa

description: Measurement of Heavy metals at Lahemaa
DOI: 10.25934/pr00010513
title: A Comparison of the Pharmacokinetics of Oral Budesonide Suspension (OBS) and Entocort® EC in Healthy Adults

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.15468/dl.t5sjhf
title: Occurrence Download

description: A dataset containing 446 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Aquatica ficta (E.Olivier, 1909)"
 ]
}

 The dataset includes 446 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022593-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00010584
title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, 2-Sequence Crossover Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry Using BOLD Functional MRI and Arterial Spin Labeling in Healthy Participants

description: The primary objective of the study is to explore the pharmacodynamic (PD) effects of BIIB104 on brain circuitry associated with emotional processing in healthy participants.The secondary objectives of the study are to evaluate the safety and tolerability of BIIB104 in healthy participants; To further explore the PD effects of BIIB104 on brain circuitry associated with emotional processing in healthy participants; To explore the PD effects of BIIB104 on brain circuitry associated with working memory in healthy participants using the N-Back; To explore the PD effects of BIIB104 on regional cerebral blood flow (CBF) in healthy participants; To explore the PD effects of BIIB104 on brain circuitry during resting state in healthy participants.
DOI: 10.25934/00005273
title: A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

description: Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
DOI: 10.25934/pr00010374
title: A COMPARATIVE, SINGLE CENTER, OPEN LABEL, LABORATORY-BLIND, RANDOMIZED, FOUR PERIOD CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF AN IMMEDIATE-RELEASE TABLET FORMULATION CONTAINING 500 MG FLUCYTOSINE AND THREE SUSTAINED-RELEASE PELLET FORMULATIONS OF FLUCYTOSINE IN HEALTHY MALES AND FEMALES UNDER FASTING CONDITIONS

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00010375
title: A COMPARATIVE, SINGLE CENTER, OPEN-LABEL, RANDOMIZED, TWO-PART (SINGLE AND MULTIPLE) STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF AN IMMEDIATE-RELEASE TABLET FORMULATION CONTAINING 500 MG FLUCYTOSINE AND A SUSTAINED RELEASE PELLET FORMULATION OF FLUCYTOSINE IN HEALTHY MALES AND FEMALES UNDER FED CONDITIONS AND AT STEADY-STATE UNDER FED CONDITIONS

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00010934
title: A Randomized, Placebo-Controlled, Double-Blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

description: This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.The purpose of this study was to find out how safe it is for these women to take fezolinetant in long term (up to 52 weeks). To do that, the study looked at the number and severity of the "adverse events." Those were the side effects that study participants had while they were in the study.The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looked like medicine but did not have any medicine in it.) Women in this study were picked for 1 of the 3 study treatments by chance alone. The study participants took study treatment for 52 weeks.This study was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo).At weeks 2 and 4 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine were collected for laboratory tests. At some study visits, study participants completed questionnaires that were about their quality of life. At the first and last study visits, they had a dual-energy x-ray absorptiometry (DXA for short) test done. To measure bone loss in the hips and spine, DXA created pictures of the inside of these areas with low-dose x-rays. (The dose was approximately one-tenth of the amount of a normal chest x-ray.) Study participants who still had their uterus had 2 more tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. It used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have had a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agreed.The last check-up at the hospital or clinic was at 3 weeks after the last dose of study treatment.
DOI: 10.15468/dl.tjffxf
title: Occurrence Download

description: A dataset containing 128 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is one of (ITA.1_1, ITA.8_1, ITA.11_1, ITA.12_1, ITA.18_1)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Carcharodus alceae (Esper, 1780)"
 ]
}

 The dataset includes 128 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0022594-250127130748423/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00010083
title: Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome

description: Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a consistent reduction in blood eosinophil counts is observed in association with mepolizumab administration, with concomitant clinical improvement. This is a 32-week treatment period, randomized, double-blind, placebo-controlled, parallel group, multicentre study of mepolizumab in adolescent and adult subjects with severe HES receiving standard of care (SoC) therapy. This study will demonstrate the efficacy of mepolizumab compared with placebo based on maintenance of control of HES symptoms during the treatment period. The study will comprise of a screening period of up to approximately 4 weeks followed by a 32-Week study treatment period (subjects will be randomized 1:1 to placebo or mepolizumab) and up to 8-week additional follow-up period (12 weeks after the last dose of study treatment).
DOI: 10.25934/pr00009933
title: A Phase 4, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety of 2 New of 6:2 Influenza Virus Reassortants in Adults

description: This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.
DOI: 10.25934/pr00010628
title: A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up

description: Parts A \& B: Conversion of stable pediatric allograft recipients from Prograf® immunosuppression to Advagraf® immunosuppression to compare exposure and one year follow-up for safety and efficacy.Part C: Continuation of long-term follow-up and provision of ongoing study medication to subjects to whom Advagraf® is currently not available.
DOI: 10.25934/pr00009970
title: A Single Arm Trial of Systemic And Subtenon Chemotherapy For Groups C And D Intraocular Retinoblastoma

description: Phase III trial to determine the effectiveness of combining systemic chemotherapy and subtenon carboplatin with ophthalmic therapy in treating children who have intraocular retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether systemic chemotherapy and subtenon (under the conjunctiva of the eye) carboplatin combined with ophthalmic therapy is effective in treating intraocular (within the eyeball) retinoblastoma.
DOI: 10.25934/pr00009979
title: A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy

description: This phase III trial is studying vincristine, carboplatin, and etoposide to see how well they work compared to observation only in treating patients who have undergone surgery for newly diagnosed retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, no additional treatment is needed for the tumor until it progresses. In this case, observation may be sufficient.
DOI: 10.25934/pr00009887
title: A Phase 1, Randomized, Open-label, Crossover Study to Assess Food Effect on Single Oral Dose Administration of TAK-385 Final Formulation in Premenopausal Healthy Adult Women

description: The purpose of this study is to evaluate food effects on the pharmacokinetics of a single oral dose of TAK-385 in Japanese premenopausal healthy adult women.
DOI: 10.25934/pr00009967
title: NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY

description: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.
DOI: 10.25934/pr00010602
title: A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study)

description: To compare how well the new formulation of Tacrolimus® used once daily, in combination with other drugs helps prevent the rejection of a new kidney after transplantation compared to the twice daily dose of Tacrolimus
DOI: 10.25934/pr00010619
title: A Multicenter, Two Arm, Randomized, Open Label Clinical Study Investigating Renal Function in an Advagraf® Based Immunosuppressive Regimen With or Without Sirolimus in Kidney Transplant Patients

description: The purpose of this study is to compare the effect of two anti-rejection therapy regimens on kidney function in kidney transplant recipients.